The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register
Open Access
- 30 August 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (9), 2929-2935
- https://doi.org/10.1002/art.22868
Abstract
Objective Anti–cyclic citrullinated peptide (anti‐CCP) antibodies are a stronger predictor of the severity of rheumatoid arthritis than is rheumatoid factor (RF). Their role in predicting outcome in unselected patients with new‐onset inflammatory polyarthritis (IP) has not been examined. The aims of this study were to examine the role of baseline RF and anti‐CCP antibodies in determining the likelihood of patients having erosions at presentation or in predicting future radiologic damage, and to determine whether anti‐CCP antibodies or RF is sufficiently robust to be clinically useful in guiding treatment decisions in early IP. Methods Patients were recruited from the Norfolk Arthritis Register. Logistic regression models were fitted to test the ability of anti‐CCP antibodies and RF to predict erosions. Further models were investigated to examine the role of anti‐CCP antibodies in patients stratified by RF status. Results The presence of anti‐CCP antibodies at baseline was strongly associated with both prevalent erosions (odds ratio [OR] 2.53 [95% confidence interval (95% CI) 1.48–4.30]) and developing erosions at 5 years (OR 10.2 [95% CI 6.2–16.9]). These ORs were higher than those for RF (OR 1.63 [95% CI 0.94–2.82] and OR 3.4 [95% CI 2.2–5.2], respectively). The likelihood ratio (LR) for the prediction of prevalent erosions and erosions at 5 years was highest in the RF−subgroup (LR 2.2 and 5.8, respectively). However, 27% of anti‐CCP−patients had developed erosions by 5 years. Conclusion Despite their strong association with the presence, development, and extent of erosions, anti‐CCP antibodies alone are not a sufficiently accurate measure upon which to base clinical treatment decisions. Knowledge of anti‐CCP antibody status is most informative in RF−negative patients.Keywords
This publication has 28 references indexed in Scilit:
- Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritisClinical Rheumatology, 2006
- Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onsetAnnals Of The Rheumatic Diseases, 2006
- Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis RegisterArthritis Research & Therapy, 2006
- Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcomeRheumatology, 2005
- Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature reviewAnnals Of The Rheumatic Diseases, 2005
- Evaluation of the 1987 revised criteria for rheumatoid arthritis in a cohort of newly diagnosed female patientsArthritis & Rheumatism, 1990
- Radiologic assessment as an outcome measure in rheumatoid arthritisArthritis & Rheumatism, 1989
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- STANFORD HEALTH ASSESSMENT QUESTIONNAIRE MODIFIED TO ASSESS DISABILITY IN BRITISH PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1986